Most clinical isolates of Staphylococcus aureus harbour genes encoding superantigenic toxins that bind the Vb domain of T-cells, but little information is available concerning superantigenic toxin production during staphylococcal toxic shock syndrome (TSS) and septic shock. This prospective study investigated 14 patients with staphylococcal TSS or septic shock; the toxin gene profile of each isolate was determined and flow-cytometry was used to identify the discriminant Vb signature (DVbS) of each superantigenic toxin in vitro. Attempts were also made to identify in-vivo production of superantigenic toxin DVbS in patients' blood. The DVbS identified in vitro were: toxic shock syndrome toxin (TSST)-1, Vb 2; staphylococcal enterotoxin (SE), Vb 9, Vb 22; SEB, Vb 3, Vb 14, Vb 17; SED, Vb 1, Vb 8; egc, Vb 5.3, Vb 7.1, Vb 9, Vb 23; and SElK, Vb 5.1. The DVbS of TSST-1 and SEB were detected in patients with menstrual and non-menstrual TSS, respectively, whereas no Vb signature was detected during septic shock. All patients with septic shock (but only one patient with TSS) had lymphopenia and ⁄ or impaired cellular immunity. Detection of a superantigenic toxin DVbS may help to show which toxin is produced during staphylococcal TSS, thus confirming the diagnosis and hastening the administration of anti-toxin therapy. In contrast, this approach failed to demonstrate superantigenic toxin involvement in cases of septic shock. In this latter condition, a superantigenic toxin may not be produced by S. aureus, or its production may occur without expansion of targeted T-cells because of T-cell apoptosis and ⁄ or anergy.
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I N T R O D U C T I O N
Staphylococcus aureus produces a wide range of toxins that interact with the immune system. Superantigenic toxins, also called pyrogenic toxin superantigens, which include toxic shock syndrome toxin-1 (TSST-1) and staphylococcal enterotoxins (SEA, SEB, etc.), mediate a potent activation of immune cells [1, 2] . These molecules bypass normal antigen presentation pathways by cross-linking major histocompatibility complex class II molecules on antigen-presenting cells to the Vb domain of the T-cell receptor [1, 2] . In this way, each superantigenic toxin selectively stimulates and expands one or several Vb subsets, thereby producing a Vb signature for each superantigenic toxin [2] [3] [4] . Except for Vb 2, which is specific to TSST-1, a given Vb subset may be expanded by different superantigenic toxins, and the discriminant Vb signature (DVbS) of each superantigenic toxin (i.e., the combination of Vb subsets specific to a given superantigenic toxin) is unknown [2] [3] [4] . The massive T-cell activation mediated by superantigenic toxins leads to uncontrolled release of pro-inflammatory cytokines, which are responsible for clinical manifestations of toxin-mediated diseases, e.g., toxic shock syndrome (TSS) [2, 5] .
TSST-1 was first identified in the 1980s as the toxin responsible for menstrual TSS, while both TSST-1 and enterotoxins are involved in nonmenstrual TSS [6, 7] . For many years, the identification of superantigenic toxins involved in TSS was based mainly on the in-vitro toxin production or toxin gene content of an isolate [6, [8] [9] [10] . However, superantigenic toxins are also produced by S. aureus isolates from patients without TSS [11] . This includes patients with septic shock, thereby adding to the controversy surrounding the involvement of superantigenic toxins in the pathogenesis of S. aureus septic shock [12] .
It has been shown previously that the in-vivo Vb signature of superantigenic toxins can be used to confirm a diagnosis of TSS [13, 14] ; indeed, expansion of Vb 2 T-cells, which corresponds to TSST-1 superantigenic activity, has been detected in patients with TSS [13] [14] [15] . Selective expansion of Vb T-cells has not yet been investigated in patients with enterotoxin-associated non-menstrual TSS or in patients with S. aureus septic shock. The purpose of the present study was to detect in-vivo production of superantigenic toxins early after onset of staphylococcal TSS and septic shock. An attempt was made to identify superantigenic toxin DVbS in peripheral blood mononuclear cells (PBMCs) of patients who had been enrolled prospectively after determination of (i) the toxin gene profile of each isolate and (ii) the DVbS obtained in vitro by flow-cytometry with the culture supernatant of the corresponding S. aureus isolate.
M A T E R I A L S A N D M E T H O D S Patients and clinical data
Patients with S. aureus TSS or septic shock were enrolled prospectively between 1 January 2006 and 31 December 2006. The study was approved by the local ethics committee. Septic shock was defined according to the criteria of the American College of Chest Physicians ⁄ Society of Critical Care Medicine Conference [16] . S. aureus TSS was defined according to CDC criteria [17] .
The following data were recorded for all patients: demographical characteristics (age, gender), underlying disorders associated with impaired cellular immunity (haematological immunosuppressive disease, ongoing malignancy, infection with human immunodeficiency virus, cirrhosis, etc.) and current corticosteroid therapy (>1 month) or other immunosuppressive therapy. Therapy with antimicrobial agents and intravenous immunoglobulin was also recorded, and the 28-day mortality rate was determined.
Microbiological investigations
S. aureus isolates from vaginal swabs and other sites of infection were identified by standard microbiological methods, including Gram's stain and use of the Phoenix Automated Microbiology System (Becton Dickinson Biosciences, Franklin Lakes, NJ, USA). Each S. aureus isolate was also tested for production of coagulase (bioMérieux, Marcy-l'Etoile, France), catalase and clumping factor (Pastorex Staph-plus; Bio-Rad, Hercules, CA, USA).
Genomic DNA was extracted from all isolates and analysed by PCR for genes encoding various superantigenic toxins, i.e., TSST-1, SEA, SEB, SEC, SED (isolates positive for the gene encoding SED were also considered to be positive for the gene encoding SEJ, as these two genes are located on the same plasmid), SEH, SElK, SElL, SElM, SElO (isolates positive for genes encoding SElM and SElO were also considered to be positive for SEG, SEI and SEN, as they form part of a single operon known as the enterotoxin gene cluster, egc), SElP, SElQ and SElR [4, 18] . The mecA gene coding for methicillin resistance was also detected by PCR [10] .
Flow-cytometry
In-vitro determination of the DVbS of individual superantigenic toxins. Culture supernatants of each clinical isolate, grown for 24 h at 37°C with vigorous shaking in RPMI-1640 medium (Invitrogen, Paisley, UK) supplemented with fetal bovine serum (Invitrogen) 5% v ⁄ v, were filtered (Sartorius 0.20-lm Minisart; VivaSciences, Hannover, Germany) and used to stimulate PBMCs (2 · 10 6 ⁄ mL) purified from two healthy donors by Ficoll density gradient sedimentation (PANCOLL; PAN Biotech GmbH, Aidenbach, Germany). After incubation for 2 days, the cells were washed twice in phosphate-buffered saline (Invitrogen) and resuspended in fresh RPMI-1640 medium supplemented with heat-inactivated fetal bovine serum 10% v ⁄ v, 20 mM HEPES buffer, 2 mM L-glutamine (Sigma-Aldrich, Poole, UK), streptomycin and penicillin (Invitrogen) 100 mg ⁄ L in 24-well Falcon plates (Becton Dickinson) for 9 days. The medium was changed every 3 days. After culture for 11 days, PBMCs were labelled with anti-CD3 and anti-Vb antibodies (24 Vb antibodies are quantified in the Immunotech IO Test b Mark; Beckman Coulter, High Wycombe, UK) according to the supplier's instructions. The Vb repertoire was determined by flowcytometry (FACScan; Becton Dickinson) and the multiparameter data files were analysed with the Cellquest program (Becton Dickinson). To assign the DVbS of a given superantigenic toxin, the Kruskal-Wallis non-parametric test was used to compare the percentage of each Vb subset, obtained for all isolates, in the presence and absence of each superantigenic toxin gene, with p <0.05 considered to be statistically significant. Finally, by combining all the results, a single Vb subset, or a combination of Vb subsets, was considered to be the DVbS of the corresponding toxin. The results obtained were compared with those published previously [3, 4, 15, [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] .
Determination of the Vb repertoire in patients with staphylococcal toxic or septic shock and detection of a superantigenic toxin DVbS in blood. The Vb repertoire of each patient was determined as early as possible during the first 10 days after the onset of symptoms. PBMCs from the patients were purified by Ficoll density gradient sedimentation and immediately labelled with anti-CD3 and anti-Vb antibodies to determine the Vb repertoire (see above). When possible, the Vb repertoire of each patient was also determined after c. 1 week in order to detect changes in the Vb pattern with time. Control values for each Vb subset were obtained using samples from 39 healthy donors. For each Vb subset, a positive cut-off value for Vb expansion in vivo was taken as the mean plus two standard deviations of the values obtained for the same Vb subset in the controls.
R E S U L T S Clinical characteristics
Fourteen patients were enrolled in this study, five with S. aureus TSS (three menstrual and two nonmenstrual cases) and nine with S. aureus septic shock. The demographical characteristics and medical histories of these patients are summarised in Table 1 . Patients with TSS had a mean age of 30 years (range 18-63 years) and no history of immunosuppression; only one patient had transient lymphopenia (patient 5), and all survived at day 28. Patients with septic shock were older (mean age 61 years, range 35-85 years) and lymphopenia was present in all eight patients tested, with four (44%) patients having a medical history of cellular immunosuppression. Five (56%) of these patients died before day 28. Except for patients 1 and 2 (who had only postural hypotension), all patients required admission to an intensive care unit and vaso-active drug therapy (e.g., norepinephrine) after fluid resuscitation.
Microbiological findings
Among the three patients with menstrual TSS (Table 1) , one received antimicrobial therapy before swabs were taken and S. aureus was not recovered. The two available isolates responsible for menstrual TSS were positive for the tst gene and for the egc locus. There were two patients with non-menstrual TSS (Table 1) ; S. aureus grew in culture from the surgical wound of patient 4, but the isolate from patient 5 was lost before the toxin gene profile could be determined. The only available isolate responsible for non-menstrual TSS possessed the sea, seb and sed genes. Among Table 1 . Introduced after Vb analysis revealed in-vivo production of superantigenic toxin (patient 4 had persistent fever and remained in shock despite treatment with clindamycin and teicoplanin, and patient 5 had persistent fever despite treatment with oxacillin and gentamicin).
the nine isolates responsible for septic shock, five harboured the sea gene (plus sed, selr, selk or selq in four cases), while two were positive only for the egc locus. One isolate was negative for all the superantigenic toxin genes tested. Among the total of 12 S. aureus isolates, four were positive for the mecA gene (three of which corresponded to the predominant hospital-acquired methicillinresistant S. aureus clone in France), and these four isolates were responsible for septic shock.
In-vitro determination of the Vb signature of superantigenic toxins
To determine which Vb subset was expanded significantly in the presence of each superantigenic toxin gene, the Vb subset obtained with an isolate positive for the gene encoding a given superantigenic toxin (e.g., the sea gene) was compared with the results obtained for the isolates negative for this gene. Using this approach, the DVbS was Vb 2 for TSST-1, Vb 9 and Vb 22 for SEA, Vb 3, Vb 14 and Vb 17 for SEB, and Vb 1 and Vb 8 for SED ( Table 2 ). The DVbS of superantigenic toxins encoded by the egc locus was Vb 5.3, Vb 7.1, Vb 9 and Vb 23. The selk and selq genes, which were always jointly present in the isolates investigated, were associated significantly with Vb subset 5.1. In contrast to the other toxins, no specific Vb T-cell expansion was revealed in response to isolates positive for SElR.
Detection of a superantigenic toxin DVbS in peripheral blood
The Vb repertoire in PBMCs from each patient with S. aureus TSS or septic shock is shown in Table 3 and Fig. 1 . A Vb 2 T-cell expansion was observed in the three patients with menstrual TSS, even when the corresponding isolates showed in-vitro expansion not only of Vb 2, but also of other Vb subsets corresponding to the production of SEA and egc-encoded superantigenic toxins. In patient 2, the percentage of the Vb 2 subset was initially less than two standard deviations above that of the controls, but rose two-fold within 9 days (Fig. 1 ). As this case fully corresponded to the case definition, it was considered that the two-fold expansion of a Vb subset, albeit less than two standard deviations above that of the controls, could result from superantigenic toxin activation. In the two non-menstrual TSS cases, the SEB DVbS was detected. Vb 3, Vb 14 and Vb 17 were g Not considered to be a Vb subset associated significantly with SElR, as the two isolates positive for selr were also positive for the sea (Vb 9 and Vb 22 were expanded, but not significantly, and even if Vb 7.2 was not associated significantly with the discriminant Vb signature of SEA in the present study, this is one of the Vb subsets targeted by SEA) and the sed genes.
expanded by more than two standard deviations above the control values in patient 4 ( Fig. 1) . In patient 5, the Vb 14 subset was expanded by more than two standard deviations above the control values, and the Vb 3 and Vb 17 subsets increased 2.5-and 1.6-fold, respectively, within 7 days, whereas no other Vb subsets increased (Fig. 1) . In patient 4, the isolate that produced SEB also produced SEA and SED in vitro, as the Vb subset corresponding to the DVbS of these toxins was expanded. No Vb expansion was observed in six of the nine cases of septic shock (Table 3 , Fig. 1 ). In the other three cases of septic shock, one showed Vb 2 and Vb 3 expansion, a second showed Vb 14 expansion, and the third showed Vb 8 expansion. In contrast to the cases of TSS, none of these expansions correlated with the results obtained with the corresponding isolates in vitro.
D I S C U S S I O N
This study revealed that nearly all the cases of TSS were associated with specific Vb expansion, whereas no specific T-cell modifications were found in patients with septic shock, despite the presence of superantigenic toxin genes in the corresponding isolates and their expression in vitro. As most clinical isolates of S. aureus responsible for TSS and septic shock harbour two or more superantigen-encoding genes [9, 12] , it was first necessary to determine the precise DVbS corresponding to each toxin. TSST-1 is known to activate only the Vb 2 subset in vitro [3, 15] . A Vb signature has also been documented for most enterotoxins in vitro, but the situation is not straightforward as: (i) a given Vb subset may be part of the Vb signature of different enterotoxins; (ii) most enterotoxins are associated with the expansion of multiple Vb subsets; (iii) some Vb subsets are considered to be major or minor components of the Vb signature of a given enterotoxin; and (iv) discriminant combinations of Vb subsets (i.e., the DVbS) are not known for each enterotoxin [2, 3] . To our knowledge, the present investigation is the first study to determine the discriminant Vb signatures of superantigenic toxins, especially enterotoxins, produced by clinical isolates of S. aureus. For example, the study revealed that only Vb 9 and Vb 22 formed the DVbS of SEA (despite previous reports of the possible expansion of 13 different Vb subsets; Table 2 ), and that only Vb 3, Vb 14 and Vb 17 comprised the DVbS of SEB (despite previous reports of the possible expansion of eight different Vb subsets; Table 2 ) [3, 22, 24] . Determining the Vb subsets expanded by more than two standard deviations above that of the controls are shown in bold; Vb subsets expanded by less than two standard deviations above the controls, but with >1.5-fold variation between two time-points, are not shown in bold; Vb subsets comprising a detected DVbS are underlined. The diagnosis of TSS could not be confirmed, as the patient was lost to follow-up after discharge (2 weeks after admission) and no information was available concerning desquamation.
c
Corresponding to the predominant clone of methicillin-resistant Staphylococcus aureus detected in France.
d
The T-cell Vb repertoire was determined once, at the onset of symptoms. e Minor expansion of Vb 2-positive T-cells (17.7%, without tst gene detection) and minor expansion of Vb 3-positive T-cells (slightly above two standard deviations of that of the controls, without expansion of Vb 14 and Vb 17 and without detection of the seb gene) were detected. The expansion of Vb 5.1 was less than two standard deviations above that of the controls, but fell 1.6-fold between the two time-points (without detection of the selk gene). The value of Vb 14 increased by more than two standard deviations (8.5%) above that of the controls between day 7 (7.02%) and day 14 (10.5%) and remained mildly elevated (11.5%) on day 28 (without expansion of Vb 3 or Vb 17 and without detection of the seb gene). The value of Vb 8 increased by more than two standard deviations (5.3%) above that of the controls between day 1 (5%) and day 11 (6.73%) (without expansion of Vb 1 and without detection of the sed gene).
DVbS by analysing the T-cell Vb repertoire in a patient's blood may therefore be a rapid (a few hours) and reliable method of detecting production of superantigenic toxins in vivo, thereby guiding the use of anti-toxin agents (e.g., antibiotics to block toxin production, or intravenous immunoglobulin to block toxin activity in vitro) [30] . At present, identification of superantigenic toxins is based mainly on detection of the corresponding gene [9] . However, most clinical S. aureus isolates responsible for TSS and septic shock harbour at least one gene encoding a superantigenic toxin if newly described enterotoxins, e.g., those encoded by the egc locus, are included [9, 11, 12, 31] .
Biological criteria are needed for early diagnosis of TSS, as the full CDC case definition of 'definite' TSS includes desquamation, which may Fig. 1 . Vb repertoire of two patients with menstrual toxic shock syndrome (TSS), two patients with non-menstrual TSS, and two patients with septic shock. The data reveal a superantigenic toxin Vb signature during TSS, but not during septic shock. , Vb expansion of more than two standard deviations above that of the controls; , Vb expansion of less than two standard deviations above that of the controls, but with >1.5-fold variation of a Vb subset between two time-points. NA, data not available; TSST-1, toxic shock syndrome toxin-1; SE, staphylococcal enterotoxin. occur only several weeks after the onset of symptoms [2, 5] . It has been proposed that other biological criteria, e.g., the absence of acute-phase antibodies against TSST-1, should be included to facilitate early diagnosis of TSS [32] . The present study revealed specific Vb 2 expansion in the three patients with menstrual TSS, which confirmed the findings of previous case reports. This specific T-cell expansion reflected a pathogenic role of TSST-1, since: (i) only TSST-1 is responsible for menstrual TSS; (ii) the isolates carried the gene encoding TSST-1; (iii) Vb 2 expansion was observed both in the patient's blood and with the culture supernatant in vitro; and (iv) TSST-1 is the only superantigenic toxin known to target the Vb 2 subset. In patient 2, who had recurrent TSS, Vb 2 expansion was only minor, perhaps because of Vb 2-positive T-cell anergy. Indeed, immunological tolerance and anergy towards a Vb targeted by a superantigenic toxin have been described in animal models challenged repeatedly with the same superantigenic toxin, and also in humans after a first episode of neonatal TSSlike exanthematous disease, which is another TSST-1-associated disease [33, 34] . Vb 3, Vb 14 and Vb 17 expansion was observed in the two cases of non-menstrual TSS. In at least one case (patient 4), specific T-cell expansion revealed SEB intoxication, as: (i) few enterotoxins (only SEB and SEC) can induce concomitant expansion of Vb 3, Vb 14 and Vb 17 [3] ; (ii) the isolate carried the gene encoding SEB; and (iii) Vb 3, Vb 14 and Vb 17 expansion was observed in the patient's blood, and it was demonstrated that these subsets corresponded to the SEB DVbS in vitro. In the second non-menstrual case (patient 5), it was not possible to clearly demonstrate the involvement of SEB, as the isolate was lost before analysis of toxin genes and culture supernatant assays could be performed. However, the patient fulfilled all the criteria for TSS (including desquamation) and, 15 days after the onset of symptom, Vb 14 expansion associated with Vb 3 and Vb 17 expansion was detected, corresponding to the SEB DVbS. It is noteworthy that this patient with TSS developed profound lymphopenia (reported infrequently during TSS) early in the disease, and that normal values returned by the time that the SEB DVbS was detected. In the early stage of the disease, transient depletion has been described before T-cell expansion, possibly following mobilisation from peripheral blood and accumulation in lymph nodes or the spleen [34] .
During septic shock, several lines of evidence suggest that superantigenic toxins and other virulence factors may act in concert, resulting in overlap between toxic shock and septic shock in a type of 'mixed shock' [35] . First, it has been shown previously that the presence of the sea gene correlates with the onset of septic shock during S. aureus infection [12] . Second, vaccination with modified SEA, SEC or TSST-1 lacking superantigenic properties confers protection in animal models of sepsis induced by S. aureus strains producing SEA, SEC or TSST-1 in vitro [36] [37] [38] . No DVbS were detected in patients with septic shock, supporting the hypothesis that superantigenic toxins are not produced in vivo during septic shock. The slight Vb expansion observed during septic shock did not correspond to that observed in vitro with the corresponding isolates. These results indicate that: (i) superantigenic toxin is not produced during S. aureus septic shock; or (ii) the Vb expansion pick time has been missed in patients with septic shock (as described in a few patients with TSS [15] ); or (iii) that superantigenic toxin production occurs without expansion of targeted T-cells. The last possibility could be explained by T-cell apoptosis and ⁄ or anergy [39] . Apoptosis is an early event during the course of septic shock, leading rapidly to profound lymphopenia [40] . All of the septic shock patients (but only one TSS patient) had lymphopenia, and four of them also had impaired cellular immunity resulting from underlying illness or immunosuppressive therapy. Minor 'expansion' of Vb 2-positive T-cells was detected in a patient infected by a strain that did not produce TSST-1. Minor expansion of Vb 14-and Vb 8-positive T-cells was also revealed in two other patients, respectively, but these 'expansions' did not correspond to any DVbS. This might be because lymphopenia results from differential apoptosis among the 24 major Vb subsets. As a consequence, during septic shock, T-cell Vb expansion in response to superantigenic toxins might be limited by apoptosis and ⁄ or by anergy, which perhaps explains why it is difficult to demonstrate superantigen involvement in this setting.
A limitation of this study was the small number of patients studied, especially patients with TSS. However, TSS is rare in France, with only one case per 10 6 inhabitants per year. Also, markers of T-cell activation, e.g., CD45RO, used in neonatal TSS-like exanthematous disease or in some TSS cases associated with TSST-1 production [14, 34] , were not employed. Activation of an expanded Vb subset may provide indications of superantigen production, and may be useful for distinguishing expansion caused by superantigen toxins from relative expansion caused by age-related changes in the T-cell repertoire or proliferative disorders, e.g., myeloma, myelodysplasic syndromes and T-cell lymphoproliferation [41, 42] . However, each patient was sampled on several occasions in order to detect short-term variations in a Vb subset that may provide information about its putative stimulation and expansion. In a previous study, Kamel et al. [43] failed to demonstrate a clear-cut correlation between results in vivo and in vitro in patients with multiple myeloma and non-menstrual toxic shock or septic shock.
In conclusion, analysis of the Vb T-cell repertoire appears to be useful for detecting the superantigenic toxin DVbS in vivo. This may help to confirm the diagnosis of TSS and hasten the administration of anti-toxin therapy. Further investigations (e.g., analysis of apoptosis of putative targeted Vb subsets) are required to demonstrate in-vivo production of superantigenic toxins during S. aureus septic shock.
